Immunomodulatory Agent
BLd Combination Therapy for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new combination therapy for multiple myeloma. The goal is to find the highest dose of the combination that can be given safely, and to see how well it works in newly diagnosed patients.
Radioactive Antibody Treatment for Multiple Myeloma
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial is for patients with newly diagnosed or relapsed multiple myeloma who will receive consolidation treatment with Bexxar, a radioactive antibody. The study will look at how patients respond to the treatment and what side effects occur.
Proteasome Inhibitor
Ixazomib for Multiple Myeloma
Recruiting1 awardPhase 2
Scottsdale, Arizona
This trial study looks at the effects of ixazomib citrate on patients with multiple myeloma who have had a relapse, but are still responsive to bortezomib. Ixazomib citrate may prevent cancer cell growth by blocking some of the enzymes necessary for cell growth.
Antimetabolite
Chemotherapy + Stem Cell Transplant for Multiple Myeloma
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of bortezomib when given together with fludarabine phosphate and melphalan with or without total marrow irradiation for patients with high-risk stage I or II multiple myeloma.
Monoclonal Antibodies
PD-1 Blockade + Dendritic Cell Fusion Vaccine + CT-011 for Multiple Myeloma
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing the safety of CT-011 and the combination of the Dendritic cell fusion vaccine and CT-011 after ASCT in patients with multiple myeloma. They are also testing to see if the combination is more successful in preventing or delaying the disease from coming back, compared to treatment with ASCT alone.
Popular Filters
Trials for Multiple Myeloma Patients
Immunomodulatory Agent
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
Trials for MM (Multiple Myeloma) Patients
Immunomodulatory Agent
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
Phase 3 Trials
Immunomodulatory Agent
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
Immunomodulatory Agent
Lenalidomide + Dexamethasone +/- Thalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial tests if lenalidomide with either standard or low-dose dexamethasone works better for new multiple myeloma patients. If not, thalidomide is added. The goal is to find effective treatments with fewer side effects. Lenalidomide plus low-dose dexamethasone has been shown to be an effective treatment for multiple myeloma, particularly in patients who are not candidates for stem cell transplantation.
Immunomodulatory Agent
Lenalidomide for Smoldering Multiple Myeloma
Recruiting4 awardsPhase 3
Anchorage, Alaska
This trial compares lenalidomide to observation in treating patients with asymptomatic high-risk multiple myeloma. It is not yet known whether lenalidomide is more effective than observation alone.
Chemotherapy
TT3-LITE Regimen for Multiple Myeloma
Recruiting4 awardsPhase 3
Little Rock, Arkansas
This trial is testing a cancer treatment called S-TT3, which uses high-dose chemotherapy to kill cancer cells. It targets patients needing strong chemotherapy and transplants. The goal is to reduce severe side effects while maintaining treatment effectiveness.
Trials With No Placebo
Immunomodulatory Agent
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.